Daily Stock Analysis, AXN, Aoxing Pharmaceutical Company Inc, priceseries

Aoxing Pharmaceutical Company Inc. Daily Stock Analysis
Stock Information
Open
0.42
Close
0.44
High
0.44
Low
0.38
Previous Close
0.42
Daily Price Gain
0.02
YTD High
0.65
YTD High Date
Jan 25, 2017
YTD Low
0.31
YTD Low Date
Jan 3, 2017
YTD Price Change
0.12
YTD Gain
37.47%
52 Week High
0.94
52 Week High Date
Jul 8, 2016
52 Week Low
0.30
52 Week Low Date
Nov 8, 2016
52 Week Price Change
-0.23
52 Week Gain
-34.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 21. 2015
0.34
Feb 27. 2015
1.06
26 Trading Days
211.22%
Link
LONG
Mar 5. 2015
1.12
Mar 20. 2015
1.72
11 Trading Days
53.99%
Link
LONG
Jun 8. 2015
2.78
Jun 9. 2015
3.13
1 Trading Days
12.59%
Link
Company Information
Stock Symbol
AXN
Exchange
NYSE MKT
Company URL
http://www.aoxingpharma.com
Company Phone
646-367-1747
CEO
Zhenjiang Yue
Headquarters
California
Business Address
1098 FOSTER CITY BLVD., SUITE 106-810, FOSTER CITY, CA 94404
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001060426
About

Aoxing Pharmaceutical Co., Inc., a specialty pharmaceutical company, engages in research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Repub...

Description

Aoxing Pharmaceutical Co., Inc., a specialty pharmaceutical company, engages in research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products comprise Zhongtongan, a capsule of herbal extraction for the indication of oral and dental pain; and Bismuth Potassium Citrate, an oral solution for the treatment of chronic gastritis and stomachache due to excessive stomach acid. Its products under development include Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone that has completed phase I and phase II clinical trial for the treatment of opioid dependence; and Tilidine/Naloxone, which is in Phase II clinical trials to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. was founded in 1655 and is headquartered in Shijiazhuang, China.